What is MiMedx Group's SG&A?

MiMedx Group (MDXG) reported SG&A of $53.23M in Q1 2026.

How has MiMedx Group's SG&A changed year-over-year?

MiMedx Group's SG&A decreased by 11.2% year-over-year, from $59.97M to $53.23M.

What is the long-term trend for MiMedx Group's SG&A?

Over 4 years (2021 to 2025), MiMedx Group's SG&A has grown at a 8.1% compound annual growth rate (CAGR), from $194.85M to $266.19M.

Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.

MiMedx Group MDXG SG&A

SG&A at other companies

IAR

Integra LifeSciencesIART

$178.24M-1.8%

Organogenesis Holdings Inc.ORGO

$65.19M-10.1%

SolventumSOLV

$827M+7.5%

VericelVCEL

$49.23M+17.8%

EnovisENOV

$282.81M+5.1%

Johnson & JohnsonJNJ

$6.03B+18.0%

Other financials

Income statement

See full

Revenue$59.0M-33.1%

Gross profit$41.6M-41.9%

Operating income-$16.0M-295%

Net income-$10.9M-255%

EPS (diluted)-$0.07-240%

Balance sheet

See full

Cash & equivalents$159.8M+50.1%

Total debt$17.6M-5.7%

Total equity$242.9M+19.8%

Total assets$308.7M+14.1%

Cash flow

See full

Operating cash flow$1.9M-64.5%

CapEx$570.0K+51.2%

Free cash flow$1.3M-73.4%

Valuation

See full

Market cap$567.48M-33.9%

Enterprise value$425.3M-44.8%

P/E18.5×-2.9×

P/S1.5×-1.0×

Profitability

See full

Gross margin81%-0.9pp

Operating margin10.2%-5.1pp

Net margin7.9%-3.5pp

FCF margin17.8%-0.5pp

Returns & leverage

See full

Return on equity13.8%-8.6pp

Debt / equity0.1×0.0×

Current ratio5.4×+0.7×

Where this comes from

Reported directly by MiMedx Group in its filing.

Tagged under the XBRL concept us-gaap:SellingGeneralAndAdministrativeExpense.

The official record: MiMedx Group’s 10-Q, filed April 29, 2026, on SEC EDGAR. View the filing →

Ask your AI about MiMedx Group's sg&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is MiMedx Group's SG&A?: MiMedx Group (MDXG) reported SG&A of $53.23M in Q1 2026.
How has MiMedx Group's SG&A changed year-over-year?: MiMedx Group's SG&A decreased by 11.2% year-over-year, from $59.97M to $53.23M.
What is the long-term trend for MiMedx Group's SG&A?: Over 4 years (2021 to 2025), MiMedx Group's SG&A has grown at a 8.1% compound annual growth rate (CAGR), from $194.85M to $266.19M.
What does SG&A mean?: Combined selling expenses (sales force, marketing, distribution) and general & administrative costs (management, legal, accounting, facilities) — the broadest opex category.